Early Soluble B-Cell Maturation Antigen (BCMA/TNFRSF17) Kinetics as a Molecular Biomarker of Treatment Response in Multiple Myeloma Patients
Laura Caponi, Maria Livia Del Giudice, Silvia Ursino, Alice Botti, Alberto Gennari, Aldo Paolicchi, Riccardo Morganti, Gabriele Buda · 2026
Read Early Soluble B-Cell Maturation Antigen (BCMA/TNFRSF17) Kinetics as a Molecular Biomarker of Treatment Response in Multiple Myeloma Patients by Laura Caponi, Maria Livia Del Giudice, Silvia Ursino, Alice Botti, Alberto Gennari, Aldo Paolicchi, Riccardo Morganti, Gabriele Buda (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13300169.txt.
Description
A blood marker shed from plasma cells may show within one month whether myeloma treatment is working. Laura Caponi and colleagues followed 100 people starting therapy for newly diagnosed or relapsed multiple myeloma in a 2026 prospective study. They tracked soluble BCMA alongside standard free light chain measures at baseline, one month, and six months.
All three markers fell after treatment began, yet only soluble BCMA separated patient groups at baseline and at one month. Patients whose marker dropped by less than half at one month had over five times the odds of a weaker six-month response. In combined models, soluble BCMA alone kept its link to response quality, supporting its use for early monitoring.
Catalog record
| CREATOR | Laura Caponi, Maria Livia Del Giudice, Silvia Ursino, Alice Botti, Alberto Gennari, Aldo Paolicchi, Riccardo Morganti, Gabriele Buda |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28533 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |